Switch theme
Sign up to access all valuation multiples
Nuvectis Pharma Inc is a biopharmaceutical company. The company is engaged in the development of innovative precision medicines for the treatment of serious conditions of unmet medical needs in oncology. It operates with one segment, focused on the development of novel targeted small molecule therapeutics for the treatment of cancer in genetically defined patient populations. Its pipeline products include NXP800, NXP900.
2020
13
Last FY Revenue n/a
LTM EBITDA -$21.7M
$167M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Nuvectis Pharma has a last 12-month revenue (LTM) of n/a and a last 12-month EBITDA of -$21.7M.
In the most recent fiscal year, Nuvectis Pharma achieved revenue of n/a and an EBITDA of -$19.8M.
Nuvectis Pharma expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Nuvectis Pharma valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | n/a | XXX | n/a | XXX | XXX | XXX |
| Gross Profit | n/a | XXX | n/a | XXX | XXX | XXX |
| Gross Margin | n/a | XXX | n/a | XXX | XXX | XXX |
| EBITDA | -$21.7M | XXX | -$19.8M | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | n/a | XXX | XXX | XXX |
| EBIT | -$21.2M | XXX | -$19.8M | XXX | XXX | XXX |
| EBIT Margin | n/a | XXX | n/a | XXX | XXX | XXX |
| Net Profit | -$20.4M | XXX | -$19.0M | XXX | XXX | XXX |
| Net Margin | n/a | XXX | n/a | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Nuvectis Pharma's stock price is $9.
Nuvectis Pharma has current market cap of $197M, and EV of $167M.
See Nuvectis Pharma trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $167M | $197M | XXX | XXX | XXX | XXX | $-1.08 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Nuvectis Pharma has market cap of $197M and EV of $167M.
Nuvectis Pharma's trades at n/a EV/Revenue multiple, and -8.4x EV/EBITDA.
Equity research analysts estimate Nuvectis Pharma's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Nuvectis Pharma has a P/E ratio of -9.6x.
See valuation multiples for Nuvectis Pharma and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $197M | XXX | $197M | XXX | XXX | XXX |
| EV (current) | $167M | XXX | $167M | XXX | XXX | XXX |
| EV/Revenue | n/a | XXX | n/a | XXX | XXX | XXX |
| EV/EBITDA | -7.7x | XXX | -8.4x | XXX | XXX | XXX |
| EV/EBIT | -7.9x | XXX | -8.4x | XXX | XXX | XXX |
| EV/Gross Profit | n/a | XXX | n/a | XXX | XXX | XXX |
| P/E | -9.6x | XXX | -10.3x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | -13.6x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialNuvectis Pharma's revenue per employee in the last FY averaged n/a, while opex per employee averaged $1.5M for the same period.
Nuvectis Pharma's rule of 40 is unknown (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Nuvectis Pharma's rule of X is n/a (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Nuvectis Pharma and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | n/a | XXX | XXX | XXX |
| EBITDA Growth | 20% | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | n/a | XXX | n/a | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | n/a | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $1.5M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Nuvectis Pharma acquired XXX companies to date.
Last acquisition by Nuvectis Pharma was XXXXXXXX, XXXXX XXXXX XXXXXX . Nuvectis Pharma acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Nuvectis Pharma founded? | Nuvectis Pharma was founded in 2020. |
| Where is Nuvectis Pharma headquartered? | Nuvectis Pharma is headquartered in United States of America. |
| How many employees does Nuvectis Pharma have? | As of today, Nuvectis Pharma has 13 employees. |
| Who is the CEO of Nuvectis Pharma? | Nuvectis Pharma's CEO is Mr. Ron Bentsur. |
| Is Nuvectis Pharma publicy listed? | Yes, Nuvectis Pharma is a public company listed on NAS. |
| What is the stock symbol of Nuvectis Pharma? | Nuvectis Pharma trades under NVCT ticker. |
| When did Nuvectis Pharma go public? | Nuvectis Pharma went public in 2022. |
| Who are competitors of Nuvectis Pharma? | Similar companies to Nuvectis Pharma include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Nuvectis Pharma? | Nuvectis Pharma's current market cap is $197M |
| Is Nuvectis Pharma profitable? | Yes, Nuvectis Pharma is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Nuvectis Pharma? | Nuvectis Pharma's last 12 months EBITDA is -$21.7M. |
| What is the current EV/EBITDA multiple of Nuvectis Pharma? | Current EBITDA multiple of Nuvectis Pharma is -7.7x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
